Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Published:2020-05 Issue:5 Volume:19 Page:402-412
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Traboulsee Anthony,Greenberg Benjamin M,Bennett Jeffrey L,Szczechowski Lech,Fox Edward,Shkrobot Svitlana,Yamamura Takashi,Terada Yusuke,Kawata Yuichi,Wright Padraig,Gianella-Borradori Athos,Garren Hideki,Weinshenker Brian G

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference30 articles.

1. Neuromyelitis optica: clinical features, immunopathogenesis and treatment;Jarius;Clin Exp Immunol,2014

2. Neuromyelitis spectrum disorders;Weinshenker;Mayo Clin Proc,2017

3. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic;Kessler;Curr Treat Options Neurol,2016

4. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis;Etemadifar;Mult Scler Int,2015

5. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders;Wingerchuk;Neurology,2015

Cited by 314 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NMOSD and MOGAD: an evolving disease spectrum;Nature Reviews Neurology;2024-09-13

2. Targeting cytokine networks in neuroinflammatory diseases;Nature Reviews Drug Discovery;2024-09-11

3. Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study;Journal of Neurology, Neurosurgery & Psychiatry;2024-09-04

4. Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases;Immunity;2024-09

5. Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO);Frontiers in Neurology;2024-08-13